CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548
Michael Weller(University Hospital of Zurich), Antonio Omuro(Johns Hopkins University), Joachim M. Baehring(Yale University), Ruta Slepetis(Bristol-Myers Squibb (United States)), Filip De Vos(University Medical Center Utrecht), Antje Wick(Heidelberg University), Gaetano Finocchiaro(Istituti di Ricovero e Cura a Carattere Scientifico), Deepti Warad(Bristol-Myers Squibb (United States)), Raju R. Raval(The Ohio State University Wexner Medical Center), David A. Reardon(Dana-Farber Cancer Institute), Jérôme Honnorat(Université Claude Bernard Lyon 1), Joachim P. Steinbach(Goethe University Frankfurt), Mustimbo Roberts(Bristol-Myers Squibb (United States)), George Ansstas(Washington University in St. Louis), Jennie Taylor(University of California, San Francisco), Ashley Sumrall(Levine Cancer Institute), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Michelle H. Lee(Syneos Health (United States)), Michael Lim(Stanford University), Lynn S. Ashby(St. Joseph's Hospital and Medical Center), Kevin Petrecca(McGill University Health Centre)
Cited by 29
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
A clinical approach to diagnosis of autoimmune encephalitis
|The Lancet Neurology|2016|4.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Paraneoplastic anti– <i>N</i> ‐methyl‐ <scp>D</scp> ‐aspartate receptor encephalitis associated with ovarian teratoma
|Annals of Neurology|2007|2.5k